CLL-Current and Emerging Therapies

Article

Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Thomas Kipps, MD

Please join us for our upcoming telephone/web education program,

CLL- Current and Emerging Therapies

on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Topics will include:

  • The goal of CLL treatment
  • How staging influences personalized treatment planning
  • Current treatment options for CLL
  • Emerging therapies and clinical trials for CLL
  • Side effects management
  • The importance of open communication with your treatment team

For more information, please contact the Leukemia & Lymphoma’s Information Resource Center at 800-955-4572 or

www.LLS.org/programs

.

Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Related Content
blood cancer

APP Addresses Management of Abnormal Uterine Bleeding in Stem Cell Transplant

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
December 18th 2024
Article

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Smoking Cessation

Tobacco Smoking Contributes to MDS Molecular Pathogenesis

Darlene Dobkowski, MA
December 7th 2024
Article

With a link to specific genetic mutations in myelodysplastic syndromes, tobacco smoking may be associated with disease progression and survival.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

blood cells on a light blue background

Obe-Cel Approval Was a ‘Major Milestone’ for ALL Treatment

Megan Hollasch
November 29th 2024
Article

An expert discusses the FDA approval of obecabtagene autoleucel—the only CAR T-cell therapy given via split dosing for patients with ALL.

blood cells on a yellow background

Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma

Tim Cortese
November 11th 2024
Article

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.

© 2024 MJH Life Sciences

All rights reserved.